Headlines this week said weight loss drug prices are falling. The underlying number is real, but it does not mean what most patients will assume.
Eli Lilly reported in its second-quarter results that worldwide revenue rose 48 percent to $23.0 billion, driven by a 60 percent increase in volume and partially offset by a 13 percent decrease in realized prices. US Zepbound revenue rose 44 percent to $4.9 billion.